PAR — Par Drugs and Chemicals Income Statement
0.000.00%
- IN₹1.20bn
- IN₹924.55m
- IN₹1.01bn
Annual income statement for Par Drugs and Chemicals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | PRESS |
Standards: | — | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 608 | 751 | 957 | 956 | 1,010 |
Cost of Revenue | |||||
Gross Profit | 389 | 463 | 293 | 368 | 628 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 456 | 621 | 808 | 763 | 851 |
Operating Profit | 152 | 130 | 150 | 194 | 159 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 147 | 127 | 151 | 195 | 179 |
Provision for Income Taxes | |||||
Net Income After Taxes | 116 | 92.1 | 113 | 145 | 134 |
Net Income Before Extraordinary Items | |||||
Net Income | 116 | 92.1 | 113 | 145 | 134 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 116 | 92.1 | 113 | 145 | 134 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 16.3 | 7.49 | 9.12 | 11.8 | 10.9 |
Dividends per Share |